Search Result

Results for "

ATR kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATM/ATR (35) Apoptosis (3) Caspase (2) Checkpoint Kinase (Chk) (1) DNA-PK (1) DNA/RNA Synthesis (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) mTOR (1) PD-1/PD-L1 (2) PI3K (1) PROTACs (2) STING (4)
By Research Areas:	Cancer (35) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Isotope-Labeled Compounds

Antibodies

Targets Recommended: ATM/ATR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19323

Ceralasertib Maximum Cited Publications 60 Publications Verification AZD6738	ATM/ATR	Cancer
Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of *ATR* kinase with an IC₅₀ of 1 nM.

HY-13902

Berzosertib 20+ Cited Publications VE-822; VX-970; M6620	ATM/ATR Apoptosis STING Caspase	Infection Metabolic Disease Cancer
Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective *ATR* kinase inhibitor. Berzosertib blocks *ATR* kinase activity, abrogates G₂/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .

HY-136270

Gartisertib 5 Publications Verification VX-803; M4344; ATR inhibitor 2	ATM/ATR	Cancer
Gartisertib (VX-803) is an ATP-competitive, orally active, and selective *ATR* inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

HY-139609

Camonsertib 2 Publications Verification RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective *ATR* kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-157941

ART0380	ATM/ATR Checkpoint Kinase (Chk) DNA/RNA Synthesis	Cancer
ART0380 is a potent, selective and orally active **ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC₅₀** of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .

HY-150617

Lartesertib 1 Publications Verification M4076; ATM Inhibitor-5	ATM/ATR STING PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

HY-161615

PROTAC ATR degrader-2	PROTACs ATM/ATR Apoptosis	Inflammation/Immunology Cancer
PROTAC ATR degrader-2 is a selective ATR PROTAC degrader. PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC₅₀ values of 22.9 nM and 34.5 nM, respectively. PROTAC ATR degrader-2 has an IC₅₀ of 29.6 nM against ATR, and its IC₅₀ values against ATM and PI3K are both greater than 2000 nM. PROTAC ATR degrader-2 induces apoptosis, DNA damage, and upregulates p53 expression. PROTAC ATR degrader-2 inhibits cancer cell proliferation through the kinase-independent function of *ATR* protein. PROTAC ATR degrader-2 is applicable to research related to acute myeloid leukemia .

HY-112198

AZ31	ATM/ATR	Cancer
AZ31 is a a potent, highly selective, and orally active ATM inhibitor with an IC₅₀ of <1.2 nM for ATM enzyme, and an IC₅₀ of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .

HY-157767

Abd110	PROTACs ATM/ATR	Cancer
Abd110 (compound 42i) is a Lenalidomide-based PROTAC ATR kinase degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs .

HY-P10280

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (ASELPASQPQPFSAKKK) is a peptide substrate for *ATR* protein kinase and can be used to detect ATR kinase activity .

HY-145312

ATR-IN-4	ATM/ATR	Cancer
ATR-IN-4 is a potent *ATR* (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC₅₀s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .

HY-144217

SKLB-197	ATM/ATR	Cancer
SKLB-197 showed an IC₅₀ value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.

HY-171745

ATR-IN-32	ATM/ATR	Cancer
ATR-IN-32 is an orally active *ATR* inhibitor. ATR-IN-32 potently inhibits the proliferation of MIA PaCa-2 cells. ATR-IN-32 exerts significant tumor growth inhibition in mice bearing LOVO and HT-29 xenografts. ATR-IN-32 can be used for the study of cancers mediated by ATR protein kinase, such as colorectal cancer, pancreatic cancer .

HY-145450

ATR-IN-9	ATM/ATR	Cancer
ATR-IN-9 is a potent inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR) extracted from patent WO2020087170A1, compound 59, has an IC₅₀ of 10 nM .

HY-144435

ATR-IN-11	ATM/ATR	Cancer
ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS). ATR-IN-11 is a promising lead compound for subsequent agent discovery targeting ATR kinase. ATR-IN-11 has the potential for the research of cancer disease .

HY-142671

ATR-IN-5	ATM/ATR	Cancer
ATR-IN-5 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .

HY-142672

ATR-IN-6	ATM/ATR	Cancer
ATR-IN-6 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .

HY-153729

ATR-IN-29	ATM/ATR	Cancer
ATR-IN-29 is a potent and orally active **ATR kinase inhibitor with an IC₅₀** value of 1 nM. ATR-IN-29 shows antiproliferative activity .

HY-147569

ATR-IN-17	ATM/ATR	Cancer
ATR-IN-17 (compound 88) is a potent *ATR* kinase inhibitor. ATR-IN-17 shows good anticancer activity in LoVo cells, with an IC₅₀ of 1 nM .

HY-147568

ATR-IN-16	ATM/ATR	Cancer
ATR-IN-16 (compound 46) is a potent *ATR* kinase inhibitor. ATR-IN-16 shows good anticancer activity in LoVo cells, with an IC₅₀ of 410 nM .

HY-147566

ATR-IN-14	ATM/ATR	Cancer
ATR-IN-14 (compound 1) is a potent *ATR* kinase inhibitor. ATR-IN-14 inhibits ATR signaling pathways downstream CHKI protein phosphorylation, with inhibition of 98.03% at 25 nM. ATR-IN-14 shows good anticancer activity in LoVo cells, with an IC₅₀ of 64 nM .

HY-144214

ATR-IN-10	ATM/ATR	Cancer
ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC₅₀ value of 2.978 μM.

HY-147567

ATR-IN-15	ATM/ATR DNA-PK PI3K	Cancer
ATR-IN-15 (compound 1) is an orally active and potent *ATR* kinase inhibitor, with an IC₅₀ of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC₅₀ values of 47, 663 and 5131 nM, respectively .

HY-169930

ATR kinase-IN-2	ATM/ATR	Cancer
ATR kinase-IN-2 (Compound I-G-27) is a **ATR protein kinase inhibitor with the K_i** of 0.01 ~ 1 μΜ and can be used for study of cancer .

HY-169931

ATR kinase-IN-3	ATM/ATR	Cancer
ATR kinase-IN-3 (Compound I-G-28) is a **ATR protein kinase inhibitor with the K_i** of 0.01 ~ 1 μΜ and can be used for study of cancer .

HY-150617A

(Rac)-Lartesertib (Rac)-M4076; (Rac)-ATM Inhibitor-5	ATM/ATR STING PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
(Rac)-Lartesertib ((Rac)-M4076) is an isoform of Lartesertib (HY-150617). Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

HY-147565

ATR-IN-13	ATM/ATR	Cancer
ATR-IN-13 (compound A9) is a potent *ATR* kinase inhibitor, with an IC₅₀ of 2 nM. ATR-IN-13 can be used for ATR kinase mediated diseases research, such as proliferative diseases and cancer .

HY-144436

ATR-IN-12	ATM/ATR	Cancer
ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with an IC₅₀ value of 0.007 μM. ATR-IN-12 displays good anti-tumor activity and significantly reduces the phosphorylation level of ATR and its downstream signaling protein. ATR-IN-12 is a promising lead compound for subsequent agent discovery targeting ATR kinase .

HY-147570

ATR-IN-18	ATM/ATR	Cancer
ATR-IN-18 (compound 2) is an orally active and potent *ATR* kinase inhibitor, with an IC₅₀ of 0.69 nM. ATR-IN-18 shows antiproliferative activity in LoVo cells, with an IC₅₀ of 37.34 nM. ATR-IN-18 has anti-tumor activity .

HY-172247

ATR-IN-31	ATM/ATR	Cancer
ATR-IN-31 is a selective *ATR* kinase inhibitor with an IC₅₀ of 7 nM. ATR-IN-31 does not significantly inhibit ATM kinase activity. ATR-IN-31 inhibits viability of prostate cancer cells.ATR-IN-31 can be used for the research of prostate cancer .

HY-13902A

Berzosertib hydrochloride 20+ Cited Publications VE-822 hydrochloride; VX-970 hydrochloride; M6620 hydrochloride	ATM/ATR Apoptosis STING Caspase	Neurological Disease Cancer
Berzosertib (VE-822) hydrochloride is an orally active, CNS-penetrant, and selective *ATR* kinase inhibitor. Berzosertib hydrochloride blocks *ATR* kinase activity, abrogates G₂/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib hydrochloride induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib hydrochloride can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .

HY-181618

ATR-IN-33	ATM/ATR	Cancer
ATR-IN-33 (compound A) is a *ATR* kinase inhibitor that can be used in tumor research .

HY-136270S

Gartisertib-d8 VX-803-d₈; M4344-d₈; ATR inhibitor 2-d₈	Isotope-Labeled Compounds ATM/ATR	Cancer
Gartisertib-d₈ (VX-803-d₈) is the deuterium labeled Gartisertib (HY-136270). Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

HY-153658

ATR-IN-27		Cancer
ATR-IN-27 (Compound I-G-12) is an ATR inhibitor with a K_i value greater than 0.01 μM but less than 1 μM. ATR-IN-27 sensitizes colorectal cancer cells to Cisplatin (HY-17394) .

HY-182017

ATR ligand 2	Ligands for Target Protein for PROTAC ATM/ATR	Others
ATR ligand 2 (Compound 26) is a ATR PROTAC ligand. ATR ligand 2 can be conjugated with E3 ligase Ligand (HY-W077589A) and linker to synthesize PROTAC ATR degrader-3 (HY-182016) .

HY-181786

ATM-IN-13	ATM/ATR	Cancer
ATM-IN-13 (A36) is an orally active, selective ATM kinase inhibitor with a human IC₅₀ of 0.3 nM. ATM-IN-13 blocks the ATM-mediated DNA double-strand break repair signaling pathway, reduces the phosphorylation levels of ATM and p53, and inhibits ATM-dependent DNA damage response. ATM-IN-13 can be used in the research of colorectal cancer .

Cat. No.	Product Name

HY-L004

Cell Cycle/DNA Damage Compound Library	3,313 compounds
DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair. MCE owns a unique collection of 3,313 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cell Cycle/DNA Damage Compound Library

3,313 compounds

DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.

MCE owns a unique collection of 3,313 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cat. No.	Product Name	Target	Research Area

HY-P10280

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (ASELPASQPQPFSAKKK) is a peptide substrate for *ATR* protein kinase and can be used to detect ATR kinase activity .

Cat. No.	Product Name	Chemical Structure

HY-136270S

Gartisertib-d8
Gartisertib-d₈ (VX-803-d₈) is the deuterium labeled Gartisertib (HY-136270). Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

Host:	Rabbit (2)
Reactivity:	Human (2)
Application:	ICC/IF (2) WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (2)
Modification:	Phosphorylated (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87024

	Phospho-ATR (T1989) Antibody (YA6717) Ataxia telangiectasia and Rad3 related antibody; Ataxia telangiectasia and Rad3-related protein antibody; ATR antibody; ATR_HUMAN antibody; FCTCS antibody; FRAP Related Protein 1 antibody; FRAP-related protein 1 antibody; FRP1 antibody; MEC1 antibody; MEC1 mitosis entry checkpoint 1 homolog antibody; Ataxia telangiectasia and Rad3 related antibody; Ataxia telangiectasia and Rad3-related protein antibody; ATR antibody; ATR_HUMAN antibody; FCTCS antibody; FRAP Related Protein 1 antibody; FRAP-related protein 1 antibody; FRP1 antibody; MEC1 antibody; MEC1 mitosis entry checkpoint 1 homolog antibody; Protein kinase ATR antibody; RAC3 antibody; Rad3 related protein antibody; SCKL antibody; SCKL1 antibody; Serine/threonine protein kinase ATR antibody; Serine/threonine-protein kinase ATR antibody;	WB, ICC/IF	Human
	Phospho-ATR (T1989) Antibody (YA6717) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-ATR (T1989).

HY-P87024A

	Phospho-ATR (T1989) Antibody (YA6717)(PBS only) Ataxia telangiectasia and Rad3 related antibody; Ataxia telangiectasia and Rad3-related protein antibody; ATR antibody; ATR_HUMAN antibody; FCTCS antibody; FRAP Related Protein 1 antibody; FRAP-related protein 1 antibody; FRP1 antibody; MEC1 antibody; MEC1 mitosis entry checkpoint 1 homolog antibody; Ataxia telangiectasia and Rad3 related antibody; Ataxia telangiectasia and Rad3-related protein antibody; ATR antibody; ATR_HUMAN antibody; FCTCS antibody; FRAP Related Protein 1 antibody; FRAP-related protein 1 antibody; FRP1 antibody; MEC1 antibody; MEC1 mitosis entry checkpoint 1 homolog antibody; Protein kinase ATR antibody; RAC3 antibody; Rad3 related protein antibody; SCKL antibody; SCKL1 antibody; Serine/threonine protein kinase ATR antibody; Serine/threonine-protein kinase ATR antibody;	WB, ICC/IF	Human
	Phospho-ATR (T1989) Antibody (YA6717) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-ATR (T1989).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: